SCHEDULE 13D/A: SAIF Partners Launches Proxy Battle to Reshape Sinovac Biotech Board, Citing Governance Failures and Shareholder Value Concerns

SAIF Partners, a significant shareholder in Sinovac Biotech Ltd., has initiated a proxy solicitation to remove current board members and elect a new slate of directors, aiming to enhance shareholder value, resume stock trading, and increase dividend distributions.

Summary

• SAIF Partners IV L.P., along with its affiliates, beneficially owns 10,780,820 common shares of Sinovac Biotech Ltd., representing approximately 15.00% of the outstanding shares.
• The reporting persons have mailed definitive proxy materials for a Special Meeting of shareholders to be held on July 8, 2025 (July 9, 2025 China Standard Time).
• The primary objectives of the proxy solicitation are to elect ten new nominees to the Board of Directors and to remove existing directors David Guowei Wang, Sven H. Borho, and any other person elected or appointed without shareholder approval after February 8, 2025.
• SAIF Partners asserts that the current Board, which took office in February 2025, does not represent the interests of all shareholders and lacks the necessary experience and industry knowledge.
• Key concerns raised include the current Board's perceived lack of expediency in resuming trading of the company's common shares, the resignation of the company's auditor, and insufficient dividend distribution.
• SAIF Partners believes the company holds 'billions of dollars of cash' and that its cash and cash equivalents are worth 'over $100 per share,' advocating for a larger dividend than the $55.00 per share special dividend declared.
• The proposed slate of nominees is presented as a 'well-balanced, highly qualified, independent and diversified Board' with extensive industry knowledge, including the company's founder and CEO, Weidong Yin.
• SAIF Partners intends to seek reimbursement from Sinovac Biotech for all expenses incurred in connection with the proxy solicitation if successful.

Sentiment

Score: 3

Explanation: The document reflects a highly negative sentiment regarding the current state of Sinovac Biotech's corporate governance, financial transparency, and shareholder liquidity, as presented by SAIF Partners. While SAIF's proposed actions aim to be positive, the underlying issues (auditor resignation, trading halt, board disputes) are severe and indicate significant operational and financial distress from a governance perspective. The score reflects the negative implications of the current situation, despite the activist investor's proposed solutions.

Positives

• SAIF Partners is actively seeking to enhance shareholder value by proposing a new board that they believe will prioritize dividend distribution and the resumption of stock trading.
• The proposed board nominees include individuals with extensive industry knowledge and experience, such as the company's founder and CEO, Weidong Yin, who has a proven track record of success in the company's development and vaccine production.
• The new board aims to represent a broader base of shareholders, including SAIF Partners (15.00%), 1Globe (9.50%), Weidong Yin (8.85%), CDH Investment (8.35%), Vivo Capital (8.21%), and Advantech Capital (8.14%), promoting balanced governance.
• The solicitation highlights the company's significant cash position, with 'billions of dollars of cash' and cash and cash equivalents valued at 'over $100 per share,' suggesting strong financial health that could support further shareholder distributions.

Negatives

• The current Board of Directors is criticized for not representing the interests of all shareholders and lacking the necessary experience and industry knowledge.
• Concerns are raised about the current Board's 'lack of expediency and transparency,' specifically regarding the failure to resume trading of the company's common shares and the lack of definitive details for the declared dividend.
• The resignation of Grant Thornton Zhitong Certified Public Accountants LLP as the company's independent registered public accounting firm on April 15, 2025, and the subsequent conclusion that prior financial statements (2021, 2022, 2023) should no longer be relied upon, is a significant negative.
• The company's inability to file its Form 20-F annual report for the fiscal year ended December 31, 2024, due to the auditor resignation, is a compliance failure.
• The current Board is accused of 'lack of industry experience and cooperation with the Company's management,' leading to instability and disruption.
• The composition of the current Board is deemed 'unbalanced and unfair shareholder representation,' with members primarily representing 1Globe and OrbiMed, potentially leading to conflicts of interest and biased decisions.
• The current Board's composition is noted as being different from the one sanctioned by the Privy Council's judgment, with no explanation provided for the inconsistencies or changes.

Risks

• Ongoing shareholder disputes and litigations could continue to divert company resources away from value creation.
• The current Board's alleged lack of effective communication with the company's management team could hinder operational efficiency and strategic execution.
• The resignation of the independent auditor and the non-reliance on previous financial statements pose significant financial reporting and compliance risks, potentially impacting investor confidence and regulatory standing.
• Failure to file the Form 20-F annual report for 2024 by the due date could lead to further regulatory penalties or delisting concerns.
• The 'unbalanced and unfair shareholder representation' on the current Board could lead to decisions that favor a limited number of minority shareholders, potentially jeopardizing the company's long-term stability and operations.
• The company's common shares have not traded for over six years, and there is no guarantee that trading will resume, impacting shareholder liquidity.
• Forward-looking statements in the proxy materials are subject to known and unknown risks and uncertainties, and there is no assurance that the plans or expectations will materialize.

Future Outlook

SAIF Partners intends to continue communicating with Sinovac Biotech and other shareholders regarding board changes and related matters. Depending on these communications, the company's financial condition, market conditions, and other factors, SAIF Partners may pursue further plans or proposals to increase shareholder value. If SAIF's nominees are elected, they are expected to work expeditiously towards the resumption of trading of the company's common shares and approving and executing a plan to distribute additional dividends.

Management Comments

• On April 22, 2025, the Company's management published a statement claiming that Grant Thornton's resignation was prompted by the current Board's statement that 'the current members of the Board are assessing certain corporate actions taken by the former board of directors of the Company after they ceded office, which caused instability in the Company's operations and disruption to the Company's compliant operations and governance.'

Industry Context

This filing highlights a significant corporate governance dispute within the biotechnology and pharmaceutical industry, specifically for a company known for its vaccine development (e.g., Covid-19 vaccine). The prolonged trading halt and auditor issues are unusual for a publicly traded company, reflecting deep-seated internal conflicts. The emphasis on cash distribution and resuming trading suggests a focus on unlocking shareholder value in a company with substantial assets but impaired market access, a situation that could be unique to companies with significant cash reserves but governance challenges.

Comparison to Industry Standards

• The prolonged trading halt of Sinovac Biotech's common shares for over six years, with the last closing price at $6.47 in 2019, is highly unusual and falls significantly below standard liquidity expectations for publicly traded companies on major exchanges like Nasdaq.
• The resignation of the independent auditor (Grant Thornton) and the subsequent non-reliance on previously issued audited financial statements for 2021, 2022, and 2023, coupled with the failure to file the 2024 annual report (Form 20-F), represents a severe deviation from standard financial reporting and corporate governance practices expected of a U.S. SEC-registered company.
• The ongoing legal disputes and the perceived 'unbalanced and unfair shareholder representation' on the current board, as alleged by SAIF Partners, indicate a corporate governance environment that is far from the best practices seen in well-governed public companies, which typically prioritize independent board oversight and broad shareholder interests.
• The call for a significant cash distribution (Heng Ren's $8.9 billion or SAIF's 'billions of dollars') while the stock is untraded and auditor opinions are withdrawn, suggests a unique situation where a company holds substantial assets but is failing to provide standard shareholder returns or market access, unlike peers that typically distribute dividends while maintaining active trading and robust financial reporting.

Management Changes

Corporate Governance

Legal Proceedings

• 1Globe Capital LLC filed a claim in the Eastern Caribbean Supreme Court in the High Court of Justice, Antigua and Barbuda, seeking declarations and orders that the OrbiMed Nominees had been duly elected at the 2017 AGM.
• The Securities and Exchange Commission (SEC) charged Chiang Li and 1Globe on May 13, 2020, for failing to disclose their increasing stake in shares of the Company and their collaboration with other shareholders.
• The Judicial Committee of the Privy Council in London, England, rendered a judgment on January 16, 2025, ruling that OrbiMed Nominees were rightfully elected to the Board at the Company's annual general meeting held on February 6, 2018.
• The Company has been engaged in multiple, ongoing legal proceedings regarding the shares issued to Vivo Capital, LLC and Prime Success, LP in 2018 since the current Board took office.

Stakeholder Impact

• **Shareholders**: Potential for increased dividends and resumption of stock trading could significantly enhance shareholder value and liquidity. However, ongoing board disputes and auditor issues create uncertainty and risk. The proposed board aims for 'fair representation of interests of all shareholders'.
• **Employees**: The document mentions that the current Board's actions have caused 'instability in the Company's operations and disruption to the Company's compliant operations and governance,' which could negatively impact employees. A more stable and cooperative board could improve employee morale and operational efficiency.
• **Customers/Suppliers**: Operational instability and governance issues could indirectly affect the company's ability to serve customers or maintain supplier relationships, particularly given its role in vaccine production. A stable board could ensure continued reliable operations.
• **Creditors**: The company's significant cash reserves are a positive for creditors, but governance issues and lack of transparent financial reporting could raise concerns about long-term financial stability and risk management.
• **Management Team**: The document highlights a lack of effective communication between the current Board and the company's management team, particularly with CEO Weidong Yin. The proposed board aims to 'build trust with the Company management and work closely with them to drive continued growth'.

Next Steps

• A Special Meeting of shareholders is scheduled for July 8, 2025 (July 9, 2025 China Standard Time) to vote on the removal of existing directors and the election of SAIF Partners' nominees.
• SAIF Partners plans to continue communicating with the Issuer and other shareholders regarding board changes and related matters.
• If SAIF's nominees are elected, they are expected to work towards the resumption of trading of the company's common shares and the approval and execution of a plan to distribute additional dividends.
• The company needs to address the auditor resignation and the failure to file its 2024 Form 20-F annual report.

Key Dates

Recommendation

Keywords

Sinovac Biotech, SAIF Partners, Proxy Solicitation, Board of Directors, Shareholder Activism, Corporate Governance, SEC Filing, Schedule 13D, Dividend Distribution, Stock Trading Resumption, Auditor Resignation, Shareholder Value, Biotech, Vaccine, China